Cargando…

Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes

IMPORTANCE: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of incident gout; however, their association with recurrent flares is unknown. OBJECTIVE: To examine the association of SGLT2i vs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jie, Choi, Hyon K., Dalbeth, Nicola, Li, Xiaoxiao, Li, Changjun, Zeng, Chao, Lei, Guanghua, Zhang, Yuqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457713/ https://www.ncbi.nlm.nih.gov/pubmed/37624597 http://dx.doi.org/10.1001/jamanetworkopen.2023.30885

Ejemplares similares

Risk of gout flares after COVID-19 vaccination: A case-crossover study
por: Li, Hui, et al.
Publicado: (2022)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

The challenges of gout flare reporting: mapping flares during a randomized controlled trial
por: Teoh, Novell, et al.
Publicado: (2019)

Racial and Sex Disparities in Gout Prevalence Among US Adults
por: McCormick, Natalie, et al.
Publicado: (2022)

Gout, flares, and allopurinol use: a population-based study
por: Proudman, Charlotte, et al.
Publicado: (2019)

Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
por: Sheu, Wayne H‐H
Publicado: (2020)

Gout. Imaging of gout: findings and utility
por: Perez-Ruiz, Fernando, et al.
Publicado: (2009)

Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
por: Lai, Shih-Wei, et al.
Publicado: (2023)

Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan
por: Chung, Mu-Chi, et al.
Publicado: (2021)

Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination
por: Lu, Jie, et al.
Publicado: (2022)

Purinergic Signaling in the Regulation of Gout Flare and Resolution
por: Li, Xiaoling, et al.
Publicado: (2021)

A glance into the future of gout
por: Sivera, Francisca, et al.
Publicado: (2022)

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
por: Murdoch, Rachel, et al.
Publicado: (2021)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
por: Uhlig, T., et al.
Publicado: (2022)

The genetics of gout: towards personalised medicine?
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Trends in Prevalence of Gout Among US Asian Adults, 2011-2018
por: Yokose, Chio, et al.
Publicado: (2023)

Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares
por: Flynn, Tanya J, et al.
Publicado: (2015)

Treatment for acute flares of gout: A protocol for systematic review
por: Tang, Hongzhi, et al.
Publicado: (2020)

Tele-monitoring flares using a smartphone app in patients with gout or suspected gout: a feasibility study
por: Pouls, Bart P H, et al.
Publicado: (2021)

Effect of omega-three supplementation on serum urate and gout flares in people with gout; a pilot randomized trial
por: Stamp, Lisa K., et al.
Publicado: (2022)

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
por: Uhlig, Till, et al.
Publicado: (2022)

Internalized and Anticipated Stigmatization in Patients With Gout
por: Kleinstäuber, Maria, et al.
Publicado: (2019)

Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
por: Chen, KangYu, et al.
Publicado: (2023)

The first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia
por: Stewart, Sarah, et al.
Publicado: (2015)

Joint Application of Multiple Inflammatory Cytokines in Diagnosis of Gout Flare
por: Yu, Hanqing, et al.
Publicado: (2023)

An Atypical Presentation of a Polyarticular Gout Flare: Case Report
por: Londono, Larua, et al.
Publicado: (2023)

The anatomical pathology of gout: a systematic literature review
por: Towiwat, Patapong, et al.
Publicado: (2019)

“What say ye gout experts?” a content analysis of questions about gout posted on the social news website Reddit
por: Derksen, Christina, et al.
Publicado: (2017)

Concurrent validity of provisional remission criteria for gout: a dual-energy CT study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Gout. Epidemiology of gout
por: Roddy, Edward, et al.
Publicado: (2010)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

Serum CA72-4 is specifically elevated in gout patients and predicts flares
por: Bai, Xueshan, et al.
Publicado: (2020)

Pharmacist knowledge of gout management: impact of an educational intervention
por: Dorris, Emma R., et al.
Publicado: (2022)

A Review of Uric Acid, Crystal Deposition Disease, and Gout
por: Perez-Ruiz, Fernando, et al.
Publicado: (2014)

Patient and clinical characteristics associated with gout flares in an integrated healthcare system
por: Rashid, Nazia, et al.
Publicado: (2015)

Role of NINJ1 in Gout Flare and Potential as a Drug Target
por: Zhang, Hongliang, et al.
Publicado: (2022)

Risk Factors for Postsurgical Gout Flares after Thoracolumbar Spine Surgeries
por: Chen, Kuan-Jung, et al.
Publicado: (2022)

Cohort study investigating gout flares and management in UK general practice
por: Finnikin, Samuel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e78vac6dcopsnfod034a8pe5mi